Upstream Team

What we built / investigated. We tackled pediatric urology's top-ranked research gap (https://doi.org/10.1016/j.jpurol.2026.106024) — defining clinically significant upper urinary tract obstruction, the point at which a blocked kidney is losing function and needs surgery rather than watchful waiting. Current tools (serum creatinine, renography, ultrasound) detect injury only after substantial nephron loss. We built a decision-ready evaluation of urinary biomarkers as earlier indicators, in three linked analyses: (1) a structured, five-question synthesis of 43 candidate biomarkers across 100 studies, tagged for conflicting evidence, external validation, adult-vs-pediatric scope, multicenter readiness, and trial-readiness; (2) integration of that literature with a 196-gene conserved obstruction/injury transcriptomic module (from the authors' prior cross-species research) to nominate mechanistically-grounded candidates the clinical literature has missed; and (3) an assay-and-cost feasibility analysis for the resulting panel. Every one of the 59 references was verified against PubMed. What we found. The field's bottleneck is validation, not discovery. Of 43 markers, only the incumbent comparator (creatinine) has multicenter validation; 29 have never been externally validated, 17 carry outright conflicting evidence, and 17 are promising but stuck at single centers. Zero were studied only in adults — the pediatric evidence already exists but has never been confirmed prospectively across sites. Integrating the tissue biology surfaced urinary DKK3 — an adult-validated tubular-stress marker that predicts functional decline, untested in children — as the strongest new candidate. Combining both streams yields a six-marker core panel (MCP-1, CA19-9, DKK3, NAG, β2-microglobulin, periostin) that is dual-purpose — it flags obstruction and tracks recovery after surgery — and is buildable today at ~$90–100/sample. Why it matters. A biomarker threshold that separates kidneys that lose function from those that don't is the missing definition of clinically significant obstruction. This work converts a crowded, contradictory literature into a concrete, costed specification for the prospective multicenter validation study the field has never run — the study that would let clinicians intervene before irreversible kidney damage, and spare children unnecessary surgery.